ED Fig. 3. Antitumour activity of drug candidates in mouse breast tumour models.

a, Drug-treatment scheme of mouse breast tumour models. b, Gross dissected mammary tumour images of the EO771 tumours from the tumour-bearing C57BL/6 mice treated with vehicle control, BML-210 (20 mg kg⁻¹), or CUDC-101 (20 mg kg⁻¹). c, IHC staining images of Ki67⁺ and cleaved Caspase 3⁺ cells in the tumour tissues. d, Gross dissected mammary tumour images of the EO771 tumours from the tumour-bearing nude mice treated with vehicle control, BML-210 (20 mg kg⁻¹), or CUDC-101 (20 mg kg⁻¹). Tumours from nude mice were harvested at day 18 post injection. e, Gross mammary tumour images of the EO771 tumours from the tumour-bearing C57BL/6 mice treated with isotype control, CUDC-101 (20 mg kg⁻¹), BML-210 (20 mg kg⁻¹), anti-CD8 (10 mg kg⁻¹) + CUDC-101 (20 mg kg⁻¹), anti-CD8 (10 mg kg⁻¹) + BML-210 (20 mg kg⁻¹), anti-CD4 (10 mg kg⁻¹) + CUDC-101 (20 mg kg⁻¹) or anti-CD4 (10 mg kg⁻¹) + BML-210 (20 mg kg⁻¹). Tumours from tumour-bearing C57BL/6 mice were harvested at day 28 post injection.